Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q2 2021 Novo Nordisk A/S Earnings Call Transcript

Aug 04, 2021 / 05:00PM GMT
Release Date Price: kr305.5 (+4.78%)
Operator

Hello, and welcome to Novo Nordisk A/S First 6 Months of 2021 Results Conference Call.

(Operator Instructions)

Today, I'm pleased to present Lars Fruergaard Jørgensen, CEO. Please go ahead with your meeting.

Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

Thank you very much, and welcome to this Novo Nordisk earnings call for the first 6 months of 2021 and the outlook for the year. I'm Lars Fruergaard Jørgensen, the CEO of Novo Nordisk.

I'd like to start by thanking you for your scheduling flexibility today as we decided to advance this earnings call as a consequence of our earlier-than-anticipated release of our results following an upgrade of both sales and operating profit.

With me today, I have our Chief Financial Officer, Karsten Munk Knudsen; Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; Executive Vice President and Head of North America Operations, Doug Langa; and finally,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot